Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva for inflammatory bowel ...
After hours: March 11 at 7:32:35 PM EDT Loading Chart for SYRE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback